Co-Diagnostics, Inc. — Form 8-K

Co-Diagnostics and UK-based ReadyGo Diagnostics announced a collaboration to evaluate combining ReadyGo's GoCollect sample-preparation technology with Co-Dx's PCR platform for blood-based molecular testing at point-of-need, initially targeting decentralized Ebola detection. No financial terms, equity stakes, or timeline for results were disclosed. The companies have begun feasibility work; success is not assured and would require separate development, validation, and regulatory approval for each new application (HIV, hepatitis B/C mentioned as potential longer-term targets).